Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06031376 |
|
Recruitment Status :
Completed
First Posted : September 11, 2023
Last Update Posted : September 11, 2023
|
Sponsor:
Hunan Cancer Hospital
Information provided by (Responsible Party):
Hunan Cancer Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | October 31, 2022 |
| Actual Study Completion Date : | March 31, 2023 |